酸盐-酸盐-氧化物通路:在减轻妊娠高血压疾病中氧化应激的潜在作用
Priscila Oliveira Barbosa1, José E Tanus-Santos2, Ricardo de Carvalho Cavalli1
1Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of São Paulo-USP, Ribeirão Preto 14049-900, SP, Brazil.
Nutrients
|May 25, 2024
概括
在绿叶蔬菜中发现的酸盐可能为妊娠高血压疾病 (HDPs) 提供一种新的治疗方法. 这种方法针对内皮功能障碍和氧化应激,有可能改善母亲和胎儿的结果.
科学领域:
- 产科和妇科 产科和妇科
- 心血管研究研究心血管研究
- 营养科学 营养科学
背景情况:
- 妊娠高血压疾病 (HDPs) 影响全球5-10%的怀孕,对母亲和胎儿的健康构成风险.
- 内皮功能障碍和氧化应激是HDPs的关键病理因素,导致氧化 (NO) 生物利用率降低和高血压.
- 目前用于HDPs的抗高血压治疗有安全问题和可变的疗效,需要替代治疗策略.
研究的目的:
- 探索酸盐-酸盐-NO路径作为HDPs的替代治疗策略的潜力.
- 讨论饮食中酸盐在管理HDPs中的潜在抗氧化作用.
- 强调富含酸盐的食物,如深色绿叶蔬菜和甜菜,作为潜在的HDP处理的来源.
主要方法:
- 这是一篇综述性文章,综合了有关酸盐-酸盐-NO通路及其与HDPs相关性的现有研究.
- 该综述侧重于将酸盐代谢与内皮功能和氧化应激联系起来的生理机制.
- 在文献中搜索和分析调查酸盐食补充剂及其对心血管参数的影响的研究.
主要成果:
- 酸盐-酸盐-NO通路是血管度和血压的关键调节者.
- 食中的酸盐可以转化为酸盐,然后转化为氧化 (NO),从而提高NO的生物可用性.
- 酸盐具有抗氧化特性,可以减轻与HDP病理生理学有关的氧化应激.
结论:
- 食酸盐作为安全有效的替代品或HDPs的辅助疗法具有前景.
- 利用酸盐-酸盐-NO通路可以改善内皮功能,减少高血压的孕妇的氧化应激.
- 进一步的临床研究是有必要的,以确定最佳的酸盐摄入量和有效性在管理HDPs.
相关概念视频
01:23Antihypertensive Drugs: Vasodilators
505
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
505
01:28Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
01:16Antianginal Drugs: Nitrates and β-Blockers
575
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
575
01:33Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
618
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
618